Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Effect of once-weekly growth hormone replacement therapy on long-term glycemic variability in severe adult growth hormone deficiency
jRCT1031230186Not yet recruiting
- Start
- Aug 2023
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Open-label, single-arm trial of somapacitan in growth hormone deficiency (GHD), sponsored by None. Primary endpoint: Change in %CV of blood glucose. Planned start Aug 2023; status: not yet recruiting.
02
Drugs
somapacitan
03
Conditions
growth hormone deficiency (GHD)
Beyond the preview
Go deeper on jRCT1031230186.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT1031230186.